Abstracts tagged "interstitial lung disease and rituximab"

Abstract Number: 1303 • 2018 ACR/ARHP Annual Meeting
Rituximab Versus Mycophenolate Mofetil in Interstitial Lung Disease Secondary to Connective Tissue Disease
Lisa Zhu¹, Shufeng Li², Laurence Gagne³, Susan Jacobs⁴, Julie Morisset³, Joshua Mooney⁵, Rishi Raj⁵ and Lorinda Chung⁶, ¹Stanford University Medical Center, Palo Alto, CA, ²Dermatology, Stanford University School of Medicine, Stanford, CA, ³Centre Hospitalier de l’Universite de Montreal, Montreal, QC, Canada, ⁴Stanford University, Palo Alto, CA, ⁵Pulmonary and Critical Care, Stanford University Medical Center, Palo Alto, CA, ⁶Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in connective tissue diseases (CTD). CTD-related ILD (CTD-ILD) has typically been treated…
Abstract Number: 1304 • 2018 ACR/ARHP Annual Meeting
Rituximab in Connective Tissue Disease – Associated Interstitial Lung Disease
Ana Catarina Duarte¹, Ana Cordeiro¹, Bruno Fernandes², Miguel Bernardes³, Catarina Tenazinha^4,5, Inês Cordeiro^4,5, Tnia Santiago^6,7, Maria Inês Seixas⁸, Ana Roxo Ribeiro⁹ and Maria José Santos^5,10, ¹Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ²Rheumatology Department, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ³Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ⁴Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, Lisboa, Portugal, ⁵Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal, Lisboa, Portugal, ⁶Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, Coimbra, Portugal, ⁷Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Coimbra, Portugal, ⁸Rheumatology Unit, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, Viseu, Portugal, ⁹Rheumatology Unit, Hospital de S. Marcos, Braga, Portugal, Braga, Portugal, ¹⁰Serviço de Reumatologia do Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbi-mortality in patients (pts) with CTD. Small studies have recently demonstrated a promising role for…
Abstract Number: 1308 • 2018 ACR/ARHP Annual Meeting
Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD):a Single Center Study of 47 Patients
Madiha Tariq¹, Sunny Patel¹, Sarwat Umer², Gloria Caldito³ and Samina Hayat⁴, ¹Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA, ²LSU Health Shreveport, Shreveport, LA, ³Neurology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, ⁴Rheumatology/Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA
Background/Purpose: Interstitial lung disease (ILD) is a fatal complication of connective tissue diseases (CTDs). Despite numerous advances in immunosuppressive agents, data on effective treatment for…
Abstract Number: 1687 • 2017 ACR/ARHP Annual Meeting
Efficacy of Rituximab for Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Study of 28 Patients
Sunny Patel¹, Samina Hayat², Gloria Caldito³ and Kristen Erickstad¹, ¹Rheumatology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, ²Rheumatology/Internal Medicine, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, ³Neurology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA
Background/Purpose: Interstitial lung disease (ILD) is a severe pulmonary complication associated with connective tissue diseases (CTDs), resulting in substantial morbidity and mortality. Despite advances in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].